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www.haematologica.org/content/105 /3/808 Ferrata Storti Foundation P rostacyclin (PGI 2 ) controls platelet activation and thrombosis through a cyclic adenosine monophosphate (cAMP) signaling cascade. However, in patients with cardiovascular diseases this protective mechanism fails for reasons that are unclear. Using both pharmacological and genetic approaches we describe a mechanism by which oxidized low density lipoproteins (oxLDL) associated with dyslipidemia promote platelet activation through impaired PGI 2 sensitivity and diminished cAMP signaling. In functional assays using human platelets, oxLDL modulated the inhibitory effects of PGI 2 , but not a phosphodiesterase (PDE)-insensitive cAMP analog, on platelet aggregation, granule secretion and in vitro thrombosis. Examination of the mechanism revealed that oxLDL promoted the hydrolysis of cAMP through the phosphorylation and activation of PDE3A, leading to diminished cAMP signaling. PDE3A activation by oxLDL required Src family kinases, Syk and protein kinase C. The effects of oxLDL on platelet function and cAMP signaling were blocked by pharmacological inhibition of CD36, mimicked by CD36-specific oxidized phospholipids and ablated in CD36 -/murine platelets. The injection of oxLDL into wildtype mice strongly promoted FeCl3-induced carotid thrombosis in vivo, which was prevented by pharmacological inhibition of PDE3A. Furthermore, blood from dyslipidemic mice was associated with increased oxidative lipid stress, reduced platelet sensitivity to PGI 2 ex vivo and diminished PKA signaling. In contrast, platelet sensitivity to a PDE-resistant cAMP analog remained normal. Genetic deletion of CD36 protected dyslipidemic animals from PGI 2 hyposensitivity and restored PKA signaling. These data suggest that CD36 can translate atherogenic lipid stress into platelet hyperactivity through modulation of inhibitory cAMP signaling.
Introduction
Myocardial infarction (MI) is characterized by platelet-driven atherothrombotic events that lead to acute occlusion of a coronary vessel. Excessive platelet activation is controlled by endothelial derived nitric oxide (NO) and prostacyclin (PGI 2 ), 1 but action of these protective agents is overcome in MI by mechanisms that are yet to be elucidated. A key risk factor for MI is dyslipidemia, which is strongly associated with a pro-thrombotic phenotype linked to atherothrombosis and platelet hyperactivity. 2, 3 The blood of high-risk individuals with dyslipidemia is characterized by increased plasma lipid peroxides, with low density lipoproteins (LDL) serving as a highly abundant carriers for these oxidatively-modified lipids. [4] [5] [6] Oxidized LDL (oxLDL) are circulating pathological ligands that can enhance thrombosis through their ability to promote platelet hyperactivity. In vitro experimentation demonstrates that these modified lipoproteins can cause direct activation of platelets and also potentiate platelet activation induced by physiological agonists such as thrombin, ADP and epinephrine. [7] [8] [9] [10] However, the potential pathophysiological importance of these observations for thrombosis in vivo remain unclear.
The scavenger receptor CD36 has emerged as a potential conduit for transducing plasma lipid stress into platelet hyperactivity and thrombosis, through the recognition of lipoprotein associated molecular patterns (LAMPs). CD36, alone or potentially in combination with Toll-Like Receptor (TLR) 2 and TLR6 drive a complex series of intracellular signaling events that are associated with platelet activation. [11] [12] [13] [14] [15] Upon ligation of CD36, Src family kinases constitutively associated with the receptor, drive the activation of Syk, Vav-1, PLCγ2, ERK5 and JNK that are associated with platelet activation. 13, [16] [17] [18] More recently, data have emerged to suggest that the signaling events promote the generation of reactive oxygen species (ROS). 14, 16, 17 ROS in turn activate ERK to drive thrombosis directly by platelet hyperactivity and caspase-dependent procoagulant activity. 18, 19 Moreover, we found that ROS diminish sensitivity to the nitric oxide (NO)-stimulated cGMP-PKG inhibitory signaling cascade to reduce the threshold for platelet activation. 17 These data suggest that the translation of atherogenic lipid stress by platelet CD36 is functionally linked to both stimulation of activatory signaling pathways and to an as of yet ill-defined modulation of inhibitory pathways. PGI 2 is the most potent endogenous regulator of platelet function with both genetic and pharmacological modulation of the pathway linked to accelerated thrombosis in vivo. 20 PGI 2 activates a cyclic adenosine monophosphate (cAMP) signaling pathway that leads to subsequent activation of protein kinase A (PKA) in platelets and results in the phosphorylation of numerous proteins, 21 linked to the inhibition of Ca2 + mobilization, dense granule secretion, spreading, integrin α IIb β 3 activation and aggregation in vitro. 20 To ensure optimal platelet function, cAMP levels are tightly regulated by the hydrolyzing enzymes phosphodiesterase (PDE)2A and 3A. The pharmacological inhibition or genetic ablation of PDE3A in murine and human platelets reduces thrombotic potential. 22, 23 Thus, factors that alter platelet inhibition by influencing cAMP synthesis or hydrolysis may be critical modulators of atherothrombosis and potentially lead to a pro-thrombotic phenotype. Given the established link between oxidized lipid stress and excessive platelet activation, the aim of this study was to determine if oxidatively modified lipoproteins could promote platelet hyperactivity through modulation of the PGI 2 /cAMP signaling pathway.
Methods

Reagents
Phospho-PKA Substrate (RRXS*/T*) Rabbit mAb and phospho-VASP-Ser 157/239 antibodies were from Cell Signaling Technology (Danvers, USA). PDE3A antibodies were from the MRC Unit (Dundee University, Dundee, UK). Anti-β-Tubulin antibody was from Millipore (Nottingham, UK). BD Phosflow Lyse/Fix Buffer was from BD Biosciences (Oxford, UK). OxPC-E06 mAb was from Avanti Polar Lipids (Alabaster, USA). FITC-labeled Rat Anti-Mouse P-selectin (CD62P) and PE-labeled JON/A antibodies were from Emfret Analytics (Würzburg, Germany). Alexa-Fluor 647 Goat anti-Rabbit IgG, Alexa-Fluor 488 Succinimidyl Ester and Pacific Blue Succinimidyl Ester were from ThermoFisher Scientific (Waltham, USA). PAR-1 peptide was from Anaspec (Fremont, USA). Anti-CD36 Antibody (FA6-152) was from Abcam (Cambridge, UK). Phosphodiesterase Activity Assay Kit was from Enzo Life Sciences (Exeter, UK). cAMP Biotrack EIA was from GE Healthcare (Buckinghamshire, UK). Horm Collagen was from Nycomed (Munich, Germany). PGI 2 and Cholesterol Assay Kit were from Cayman Chemical (Cambridge, UK). Vena8 Endothelial+ biochips were from Cellix (Hertfordshire, UK). All other reagents were from Sigma-Aldrich (Dorset, UK).
Experimental animals
CD36 -/mice were provided by Prof. Maria Febbraio (University of Alberta, Canada). C57BL/6 were from Charles River (Kent, UK). For high-fat diet studies, male mice were fed a 45% Western diet (Special Diet Services) for 12-16 weeks. Sex/age-matched littermates were fed a normal chow for the duration of the experiments and used as controls. For all remaining experiments, male C57BL/6 and CD36-/-were used at eight weeks of age.
Isolation and oxidation of plasma low density lipoproteins
Low-density lipoproteins (density 1.019-1.063 g/mL) were prepared from fresh human plasma by sequential density ultracentrifugation and oxidised with CuSO 4 (10 mmol/L). 14 Separate preparations of LDL were used to repeat the individual experiments.
Platelet aggregation, flow assays, flow cytometric analysis, intravital microscopy, immunoprecipitation, immunoblotting, phosphodiesterase enzyme activity assay and cyclic adenosine monophosphate measurement
Detailed methods are presented in the Online Supplementary Methods.
Statistical analysis
Experimental data was analyzed by Graphpad Prism 6 (La Jolla, CA, USA). Data are presented as means±standard error of the mean (SEM) of at least three different experiments. Differences between groups were calculated using Mann-Whitney U Test or Kruskal-Wallis Test for non-parametric testing and statistical significance accepted at P≤0.05.
All studies were approved by the Hull York Medical school Ethics committee and University of Leeds Research Ethics committee.
Results
Oxidized low density lipoproteins cause platelet hyposensitivity to prostacyclin
Treatment of human washed platelets with PGI 2 (20 nM) for one minute (min), at a time point that induces maximal cAMP-mediated signaling 24 reduced thrombin (0.05 U/mL)-induced aggregation from 89.0±4.1 to 9.4±4.4% (P<0.01) ( Figure 1A ). Next, platelets were treated with oxLDL or control native LDL (nLDL) (50 mg/mL) for 2 min prior to the addition of PGI 2 (20 nM) and thrombin (0.05 U/mL). The presence of oxLDL caused a partial recovery in thrombin-stimulated platelet aggregation to 50.0±9.3 (P<0.015 vs. control), without stimulating aggregation directly ( Figure 1A) . In contrast, PGI 2 -mediated inhibition was unaffected by nLDL (5.8±1.2%). Similar data were obtained when platelets were stimulated with collagen (Online Supplementary Figure S1 ). Next, the effects of oxLDL in whole blood were examined. Stimulation of whole blood with PAR-1 peptide (10 mM) increased P-selectin expression, which was reduced by pre-treatment with PGI 2 (20 nM). Consistent with the aggregation experiments, oxLDL reduced inhibitory effects of PGI 2 ( Figure 1B) . Finally, the effects of oxLDL under physiological conditions of arterial flow were examined. Perfusion of whole blood over collagen-coated biochips led to platelet deposition and thrombus formation ( Figure 1C) , with surface coverage inhibited by PGI 2 (20 nM) from 14.9±2.9 to 3.8±1.7% (P<0.05). OxLDL, but not nLDL, prevented PGI 2 -mediated inhibition of platelet deposition (8.1±1.9%; P<0.05 compared to PGI 2 alone). OxLDL alone caused a small but non-significant increase in thrombosis and was incorporated into the thrombi as evidenced by staining for oxidized lipid epitopes ( Figure 1D ). These data demonstrate that under a variety of different conditions oxLDL reduces platelet sensitivity to PGI 2 .
Oxidized low density lipoproteins modulate cyclic adenosine monophosphate signaling through increased phosphodiesterase 3A activity
PGI 2 inhibits platelets through the stimulation of cAMP-PKA signaling cascade. 20 Given the reduced platelet sensitivity to PGI 2 , the direct effect of oxLDL on platelet cAMP metabolism was tested. Incubation with PGI 2 caused a significant increase in platelet cAMP concentrations (1814±166 fmol cAMP/1x10 8 platelets; P<0.05 vs. basal). When platelets were treated with nLDL (50 mg/mL), the ability of the prostanoid to elevate cAMP was unaffected (1885±203 fmol cAMP/1x10 8 platelets), while oxLDL (50 mg/mL) prevented PGI 2 -induced accumulation of cAMP (481±23 fmol cAMP/1x10 8 platelets; P<0.05 compared to PGI 2 alone) and also reduced basal cAMP concentrations (not significant) ( Figure 2Ai ). To determine if oxLDL blocked cAMP synthesis or accelerated cAMP breakdown by phosphodiesterase 3A (PDE3A) and PDE225, 25 the PDE2A inhibitor EHNA (20 mM) and the PDE3A inhibitor milrinone (10 mM) were used. Consistent with previous studies, both inhibitors potentiated cAMP CD36 activates platelet PDE3A haematologica | 2020; 105(3) 811 26, 28 OxLDL reduced cAMP levels in the presence of EHNA (2645±122 to 488±7623 fmol cAMP/1x10 8 platelets; P<0.05), but failed to prevent cAMP accumulation in the presence of milrinone (4761±170 to 4386±15723 fmol cAMP/1x10 8 platelets; P<0.05 ) (Figure 2Aii and 2Aiii ). To confirm that the reduction in cAMP accumulation was not restricted to PGI 2 , platelets were stimulated with forskolin, which increases cAMP in a receptor-independent non-compartmentalized mechanism. Forskolin (10 mM)-stimulated elevation in cAMP was prevented by preincubation with oxLDL (9506±526 to 4506±1136 fmol cAMP/2x108 platelets; P<0.05) ( Figure 2B ). Next, the effects of oxLDL on cAMP signaling were assessed. m (50 nM) induced robust phosphorylation of a number of PKA substrates with apparent molecular weights of: 150, 100, 75, 70, 50, 37 and 20kDa ( Figure 2C upper panel), and specifically vasodilator-stimulated phosphoprotein (VASP) (phosphoVASP-ser157) ( Figure 2C Figure S2 ). Using a concentration that produced an equivalent quantity of intracellular cAMP (Online Supplementary Figure S3 ) as m (50 nM), 8-CPT-6-Phe-cAMP caused robust phosphorylation of PKA substrates, which were unaffected by oxLDL ( Figure 2D ). These data suggest that oxLDL may regulate platelet sensitivity to m through modulation of the cAMP-signaling cascade by PDE3A.
CD36 is required for oxidized low-density lipoprotein modulation of cyclic adenosine monophosphate signaling
Previously, we and others have shown that CD36 transduces the effects of oxLDL into platelet hyperactivity. 14, 18, 28, 29 To examine the role of CD36 in linking oxLDL to altered cAMP signaling, we used a three-pronged strategy: (i) the CD36-blocking antibody FA6-152; (ii) the oxidized phospholipid oxPCCD36, a CD36-specific pathological ligand present in oxLDL, 26 and (iii) murine platelets deficient in CD36 (Online Supplementary Figure S4 ). This strategy, particularly the use of oxPCCD36, was used to account for differences in human and murine platelet sensitivity to human oxLDL. PGI 2 induced a robust phosphorylation of both the preferred ser 157 site and the alternative PKA phosphorylation site ser 239 in human platelets, 30 which was reduced significantly by oxLDL. The presence haematologica | 2020; 105(3) Figure 3A and B) . OxPCCD36 (25 mM), but not the control lipid, PAPC (25 mM), diminished phospoVASP-ser157 in response to PGI 2 ( Figure 3C ). Thrombin-induced aggregation of wild-type (WT) and CD36 -/platelets was indistinguishable, and and PGI 2 (20 nM) caused complete inhibition of aggregation with only shape change remaining ( Figure 3D and E). However, in CD36-deficient platelets, oxPCCD36 (25 mM) did not influence the inhibitory effects of PGI 2 (Figure 3E ). To confirm the mechanism underpinning these observations, we examined cAMP signaling. PGI 2 (20 nM) caused a significant increase in cAMP in both WT and CD36 -/platelets (4382±175 and 4128±366 fmol cAMP/1x10 8 platelets). Preincubation with oxLDL, but not nLDL, reduced cAMP accumulation in WT mice (3347±294 fmol cAMP/1x10 8 platelets; P<0.05) but not CD36 -/-(4196±224fmol cAMP/1x10 8 platelets) ( Figure 3F ). Furthermore, PGI 2 -induced phosphoVASP-ser157 ( Figure  3G ) and ser239 (Online Supplementary Figure S5) were reduced by oxLDL in WT but not CD36 -/platelets.
Atherogenic lipid stress induces platelet phosphodiesterase 3A activity through a mechanism that requires CD36, Src kinases and protein kinase C
Our data suggested that ligation of CD36 could activate PDE3A. We tested this directly measuring enzymatic activity of PDE3A immunoprecipitated from platelets treated with either oxLDL or oxPCCD36. PDE activity in the immunoprecipitated samples was blocked by milrinone confirming enzyme activity was due to PDE3A (Online Supplementary Figure S6 ). OxLDL (10-100 mg/mL) caused a concentration-dependent increase in PDE3A activity ( Figure 4A, left) , which plateaued at 50 mg/mL (24±6.8%; P<0.05 compared to basal) and was maintained at 27.7%±8.5 above basal for up to 60 min (longest time tested) ( Figure 4A, right) . This was strikingly different from the physiological agonist thrombin which induced a rapid induction of PDE3A activity that peaked at 1 min before returning to basal after 5 min (Online Supplementary Figure S7) .
To link the sustained activation of PDE3A to decreased cAMP levels, we assessed the cyclic nucleotide concentrations over time. Platelets were incubated with oxLDL for up to 60 min, followed by a 1 min treatment with PGI 2 (50 nM) before measuring cAMP concentrations. The preincubation of platelets with oxLDL, but not nLDL (data not shown), for up to 60 min significantly blunted PGI 2 -induced increases in cAMP with concentrations remaining at basal levels for the time course ( Figure 4B ). To confirm the role of CD36 in the activation of PDE3A, experiments were repeated with oxPCCD36. In human platelets, oxPCCD36 (25 mM), but not PAPC (25 mM), increased PDE3A activity (26.9±7.3%; P<0.05 compared to basal and PAPC) ( Figure  4C ). Critically, oxPCCD36 stimulated activity in WT platelets to 25.4±2.4% (P<0.05 compared to basal or PAPC) but not in CD36 -/platelets ( Figure 4D) .
We previously described a CD36-specific signaling pathway that includes the sequential activation of Srcfamily kinases (SFK), Syk, PLCγ2 and protein kinase C (PKC) 17 and investigated whether these kinases were involved in the activation of PDE3A. The non-selective SFK inhibitor, dasatinib (10 mM), ablated oxPCCD36induced PDE3A activation ( Figure 4E ), while the Syk inhibitor, R406 (1 mM), caused significantly reduced PDE3A activity ( Figure 4F) . Given that CD36 signaling leads to PKC activation in a SFK manner, and that PDE3A is a target of PKC in platelets, 31 we tested the PKC inhibitors RO318220 (10 mM) and BIM1 (10 mM), and the intracellular Ca 2+ chelator BAPTA-AM (20 mM) ( Figure  4G ). These three inhibitors blocked PDE3A activity induced by oxLDL, suggesting a PKC-dependent pathway (P<0.05). Platelet PDE3A activation is associated with phosphorylation of key serine residues. 31 We examined two of the most characterised sites, ser 312 (PKA and PKC sensitive) and ser 428 ( PKC sensitive). OxLDL led to a timedependent phosphorylation of ser 428 which peaked at 2 min and was still evident at 10 min, but had no effect on phosphoPDE3Aser 312 . In comparison, thrombin (0.1 U/mL) induced significantly less phosphorylation at ser 428 , which peaked at 1 min before returning to basal at 2 min ( Figure  4H ) but also induced phosphorylation of ser312. These data confirm that oxLDL and its associated oxidized phospholipids require the sequential ligation and activation of CD36, Src, Syk and PKC to activate PDE3A.
Dyslipidemia is associated with platelet prostacyclin hyposensitivity in mice
To demonstrate the functional importance of our observations on dyslipidemia-driven thrombosis, we examined platelet sensitivity to PGI 2 in mice fed a Western diet (45%). cAMP signaling, integrin αIIbβ3 activation and thrombosis were assessed in whole blood ex vivo, which allowed us to evaluate platelet function and thrombotic potential while avoiding any confounding effects of altered PGI 2 synthesis in vivo associated with dyslipidemia. 32 Western diet significantly raised cholesterol levels (Online Supplementary Figure S8 ) and the presence of oxidized phospholipids in the plasma ( Figure 5A ). We then investigated the effect of dyslipidemia on cAMP signaling using multiplexed phosphoflow cytometry to allow the examination of signaling in the physiological conditions of whole blood. 24 Platelets from high-fat fed WT animals produced significantly less phosphoVASPser 157 when challenged with PGI 2 (100 nM) than normal chow WT mice (4.9±0.4 fold vs. 6.2±0.2-fold increase over basal; P<0.05) ( Figure 5B ). The deletion of CD36 protected cAMP signaling in dyslipidemic blood, with phosphoVASP-ser 157 remaining at control levels ( Figure 5B ). In parallel experiments, blood was stimulated with CRP-XL (10 mg/mL) in the presence and absence of PGI 2 (100 nM), and αIIbβ3 activation was measured. In normal chow WT blood, PGI 2 caused 75.7±3.9% inhibition of integrin activation (P<0.05 compared to absence of PGI 2 ), which was blunted in high-fat fed WT blood (43.1%±7.6 inhibition, P<0.05 compared to normal chow) ( Figure 5C , left). Conversely, in CD36 -/blood, PGI 2 induced inhibition of integrin activation was not significantly different in normal chow and high-fat fed conditions (66.5±8% and 79.3±6.5%, respectively) ( Figure 5C , 1 st and 2 nd left).
When we assessed ex vivo thrombosis under flow, normal chow WT blood formed small thrombi on immobilized collagen in a time dependent manner, which was abolished by PGI 2 (20 nM) (Figure 5Di ). High-fat fed WT blood showed an accelerated thrombotic response with increased surface area (11±3.6% compared to 16.2±4.3% at 2 mins). In addition, dyslipidemia caused significant hyposensitivity to PGI 2 , with the prostanoid causing 31.7±10.7% inhibition compared 61.6±5.6% with normal chow (P<0.05; 2 min) (Figure 5ii and iii) . In contrast, accelerated platelet deposition on collagen and platelet hyposensitivity to PGI 2 was not detected in CD36 -/highfat fed blood ( Figure 5D ). We repeated the experiments with 8-CPT-6-Phe-cAMP. If PDE3A activation was responsible for the increased thrombotic potential associated with reduced sensitivity to PGI 2 , then CPT-6-Phe-cAMPmediated inhibition of thrombosis would be unaffected by dyslipidemia. The cAMP analog caused a similar degree of inhibition of thrombosis in all genotypes but critically remained unaffected in the context of dyslipidemia (WT-normal chow, 65.6±11.2%; WT-Western diet, 62.3±7.7%; CD36 -/--normal chow, 70.4±2.0%; CD36 -/--Western diet, 62.3±5% inhibition) (Online Supplementary Figure S9 ). Here we show a physiological role for platelet CD36 in dyslipidemia, where it drives a phenotype of platelet hyperactivity by blocking cAMP-mediated inhibition.
Oxidized low density lipoprotein potentiation of thrombosis in vivo is prevented by inhibition of phosphodiesterase 3A
To examine the role of oxLDL in thrombosis in vivo we used intravital microscopy following ferric chlorideinduced carotid artery injury. Tail-vein injections of oxLDL (2.5 mg/kg -1 bodyweight) 33, 34 into WT mice accelerated post-injury thrombotic response at all time points compared to control PBS injection (Figures 6A-C and Online Supplementary Videos S1 and S2). Next animals were pretreated with milrinone to explore in principle whether PDE3A inhibition might diminish prothrombotic effects of oxLDL. Consistent with previous studies, modulation of PDE3A activity reduced murine thrombosis ( Figure 6A -C). 23 Importantly, the presence of milrinone (10 mmol/L) significantly reduced the ability of oxLDL to promote thrombosis at all time points post injury (P<0.05) (Online Supplementary Video S3) suggesting the heightened thrombotic response in the presence of oxLDL could be related, at least in part, to changes in PDE3A activity.
Discussion
The presence of oxidized lipid epitopes, including oxLDL, is thought to promote platelet hyperactivity in subjects with obesity, CAD and stroke. 5, 6, 35 It has been established that oxidative modifications are a hallmark of dyslipidemia and that they stimulate platelet activation directly through a number of distinct receptors. 6, 8, 13 Interestingly, platelets from patients with CAD and dyslipidemia show a reduced sensitivity to the inhibitory effects of PGI 2 . These observations, coupled to pharmacological trials indicating that suppression of endothelial PGI 2 synthesis increased rate of atherothrombotic events, [36] [37] [38] [39] suggest that platelet sensitivity to PGI 2 could play an undefined role in the development of atherothrombotic events. Hence, the aim of this study was to investigate whether oxLDL may promote unwanted platelet activation through the modulation of platelet sensitivity to PGI 2 . Using a combination of pharmacological and genetic approaches, we show that oxidative lipid stress modulates platelet cAMP signaling leading to increased platelet activation. Our key findings include: (i) oxLDL and oxidized phospholipids decrease platelet sensitivity to PGI 2 , which is coupled to reduced platelet accumulation of cAMP and PKA mediated signaling; (ii) PGI 2 hyposensitivity likely occurs via sustained activation of the cAMP hydrolysing enzyme PDE3A in response to oxLDL; (iii) the activation of PDE3A by oxLDL requires ligation of CD36; and (iv) that dyslipidemia induces platelet hyposensitivity to PGI 2 in a CD36-dependent manner.
In the first instance, we used three increasingly physiological systems to show that exposure of platelets to oxLDL opposes the inhibitory effects of PGI 2 . In contrast, oxLDL failed to affect platelet inhibition by 8-CPT-6-Phe-cAMP, a PDE-resistant cAMP analog, demonstrating firstly that the PKA signaling was intact and secondly that the effects of the oxidized lipoprotein may regulate cAMP availability. Exploration of the underlying mechanisms demonstrated that OxLDL prevented the accumulation of cAMP in response to both PGI 2 and forskolin. Forskolin increases cAMP in a receptor-independent manner, thereby providing evidence that oxLDL did not affect the interaction of PGI 2 with the IP receptor or target adenylyl cyclases. This is consistent with previous studies demonstrating that reduced platelet sensitivity to PGI 2 in patients with hypercholesterolemia was independent of any changes in cAMP synthesis by adenylyl cyclase. 36 It was therefore possible that oxLDL could either prevent the synthesis of cAMP or accelerate its breakdown. We further found that oxLDL failed to modulate cAMP concentrations in the presence of the PDE3 inhibitor milrinone, but not the PDE2 inhibitor EHNA, suggesting that cAMP hydrolysis by PDE3A was the potential mediator of PGI 2 hyposensitivity. A role for PDE3A was confirmed using immunoprecipitation experiments showing that both oxLDL and oxPCCD36 accelerated the hydrolytic activity of PDE3A in both human and murine platelets through ligation of CD36. The activation of PDE3A downstream of CD36 required the activation of Src family kinases, Syk and PKC. This provides further evidence that CD36-SFK-Syk represents a multiprotein complex that transduces extracellular oxidative lipid stress to the intracellular signaling machinery of the platelet. Interestingly, hemostatic agonists such as thrombin and collagen also activate PDE3A through a PKC-dependent mechanism. 31 These agonists are proposed to cause a rapid attenuation of cAMP signaling at sites of vascular injury to promote platelet-mediated hemostasis. However, in contrast to the rapid and short-lived activation of PDE3A activity by thrombin and collagen, oxLDL induced a sustained PDE3A response for up to 60 min (longest time tested). This was linked to a different activatory phosphorylation pattern of PDE3A by oxLDL and could suggest a distinct mechanism of activation induced by short-lived hemostatic agonists from that of oxLDL. Given the sustained activation of platelet PDE3A in the presence of oxidative lipid stress, it is attractive to speculate that PDE3A may be partially activated in dyslipidemic disease states and thereby reduce the threshold for platelet activation by diminution of cAMP. Indeed, gain of function mutations of PDE3 are associated with stroke, underlining its role in vascular pathology. 40 This concept is also supported by observations that inhibition of PDE3A by cilostazol can have beneficial anti-thrombotic effects in high-risk groups characterized a prothrombotic phenotype. [41] [42] [43] The pathophysiological consequences of platelet hyposensitivity to PGI 2 and the potential importance of CD36 was explored in a murine model of high-fat feeding-induced dyslipidemia. Interestingly, we found that even mild dyslipidemia was characterized by the presence of oxidized lipid epitopes in the plasma, which was unaffected by the absence of CD36. Whole blood phosphoflow cytometry was used to measure platelet phosphoVASP, as a marker of cAMP signaling, without the need for cell isolation. This demonstrated that mild dyslipidemia was accompanied by reduced cAMP signaling. The functional importance of this blunted cAMP signaling response manifested as diminished platelet sensitivity to the inhibitory effects of PGI 2 on integrin activation measured by flow cytometry and ex vivo thrombosis. The assessment of thrombosis ex vivo was important to demonstrate that hyposensitivity of platelets to PGI 2 was a primary platelet defect rather than a response to a dysfunctional endothelium, where altered PGI 2 production has been observed in models of dyslipidemia. 32 To support our hypothesis that hyposensitivity to PGI 2 was linked to PDE3A activity, we showed that cAMP signaling in dyslipidemia was normal if a PDE-resistant cAMP analog (8-CPT-6-Phe-cAMP) was used, again confirming that PKA signaling downstream of cAMP was functional. Critically, genetic ablation of CD36 protected animals from the loss of PGI 2 sensitivity and restored PKA signaling. Infusions of oxLDL into wild-type mice caused a robust potentiation of thrombosis by ferric chloride. However, mice were protected from the prothrombotic effects of oxLDL in vivo when PDE3A was pharmacologically inhibited. Using this approach, milrinone did not target only platelets and could therefore have an effect on other PDE3A expressing cells. However, the data are proof of principle that the prothrombotic effects of oxLDL in vivo, at least in part, may be prevented by therapeutic strategies based on enhancing or preserving cAMP signaling events in platelets. This element of the work requires further studies focussing on strategies for the specific targeting of PDE3A, and potentially PDE2, in platelets.
Together, our ex vivo and in vitro data suggest a previously unrecognized mechanism contributing to platelet hyperactivity, where the ligation of CD36 by oxidized lipids modulates cAMP signaling by activating PDE3A leading to PGI 2 hyposensitivity. These data may constitute a link to the observed PGI 2 hyposensitivity in dyslipidemic high-risk populations and indicate a novel therapeutic strategy to target atherothrombotic risk in certain patient groups. Remarkably, current antiplatelet therapy exclusively targets platelet activatory pathways including cyclo-oxygenases (Aspirin), P2Y12 (Thienopyridines, non-Thienopyridines) or α IIb β 3 (Tirofiban; Eptifibatide) while platelet inhibitory pathways remain untargeted. Therefore, high-risk populations might remain at increased atherothrombotic risk despite optimal available pharmacological therapy, and impaired platelet inhibition might contribute to the residual cardiovascular risk.
